Induction of 70‐point clinical response CDAI · Patients with active Crohn's disease
Low dose naltrexone may leads to higher induction of 70‐point clinical response CDAI compared with placebo (low certainty).
1 finding from 1 review
Induction of 5‐point endoscopic response CDEIS · Patients with active Crohn's disease
Low dose naltrexone may leads to higher induction of 5‐point endoscopic response CDEIS compared with placebo (low certainty).
1 finding from 1 review
Sleep disturbance (adverse event) · Patients with active Crohn's disease
Low dose naltrexone showed no clear difference in sleep disturbance (adverse event) compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse outcomes · Patients with active Crohn's disease
Low dose naltrexone showed no clear difference in withdrawals due to adverse outcomes compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality Up to 28 days following admission · the prevention and treatment of bleeding in patients without haemophilia
FIBRINOGEN: Therapeutic trials: intervention showed no clear difference in all‐cause mortality Up to 28 days following admission compared with inactive Control (moderate certainty).
1 finding from 1 review
Arterial thrombotic events ‐ up to 30 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
FIBRINOGEN: Prophylactic trials: intervention showed no clear difference in arterial thrombotic events Up to 30 days post‐operatively compared with inactive control (low certainty).
2 findings from 1 review
Venous thrombotic events Up to 4 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
1 finding from 1 review
Arterial thromboembolic events at 1 to 2 years · the prevention and treatment of bleeding in patients without haemophilia
1 finding from 1 review
Arterial thromboembolic events ‐ Duration of hospital stay (whole population) · the prevention and treatment of bleeding in patients without haemophilia
1 finding from 1 review
Venous thromboembolic events · the prevention and treatment of bleeding in patients without haemophilia
1 finding from 1 review
Venous thromboembolic events Duration of hospital stay (whole population) · the prevention and treatment of bleeding in patients without haemophilia
1 finding from 1 review
Arterial thromboembolic events Post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
FXIII: Prophylactic trials: intervention showed no clear difference in arterial thromboembolic events Up to 5 to 7 weeks post‐operatively compared with inactive control (low certainty).
3 findings from 1 review
RR 0.67 [0.28, 1.62]
2 studies · 282 participants
Low
RR 3 [0.14, 66.53]
1 study · 22 participants
Low
RR 0.2 [0.01, 3.97]
1 study · 50 participants
Very low
All‐cause mortality In‐hospital mortality up to 30 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
FIBRINOGEN: Therapeutic trials: intervention showed no clear difference in all‐cause mortality In‐hospital mortality up to 30 days… compared with inactive Control (low certainty).
1 finding from 1 review
Venous thromboembolic events · the prevention and treatment of bleeding in patients without haemophilia
FXIII: Prophylactic trials: intervention showed no clear difference in venous thromboembolic events ‐ Up to 5 to 7 weeks post‐operatively compared with inactive control (low certainty).
2 findings from 1 review
Venous thromboembolic events Up to 30 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
FXIII: Prophylactic trials: intervention showed no clear difference in venous thromboembolic events Up to 30 days post‐operatively compared with inactive control (low certainty).
1 finding from 1 review
All‐cause mortality Up to 6 weeks post‐natally · the prevention and treatment of bleeding in patients without haemophilia
1 finding from 1 review
All‐cause mortality Up to 28 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
FIBRINOGEN: Therapeutic trials: intervention showed no clear difference in all‐cause mortality Up to 46 days post‐operatively compared with inactive Control (high certainty).
1 finding from 1 review
All‐cause mortality Up to 7 days post‐operatively or hospital discharge · the prevention and treatment of bleeding in patients without haemophilia
1 finding from 1 review
All‐cause mortality Up to 28 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
2 findings from 1 review
Venous thromboembolic events Up to 30 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
1 finding from 1 review